Trial Profile
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary) ; Sarilumab (Primary)
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms EMPOWER
- 07 Nov 2023 Planned End Date changed from 26 Sep 2029 to 3 Nov 2026.
- 07 Nov 2023 Planned primary completion date changed from 26 Sep 2025 to 3 Nov 2025.
- 07 Nov 2023 Status changed from active, no longer recruiting to recruiting.